Just out in @bmj.com, our "Uncertainties in Practice" article on #LATP vs #TRUS
We highlight evidence so far, discordance between recommendations (@UroWeb.bsky.social vs @NIHR.bsky.social vs #AUA) & need for nuance (!)
Not long now until #TranslateTrial...
bmj.com/content/387/bm…👈
We highlight evidence so far, discordance between recommendations (@UroWeb.bsky.social vs @NIHR.bsky.social vs #AUA) & need for nuance (!)
Not long now until #TranslateTrial...
bmj.com/content/387/bm…👈
December 2, 2024 at 3:34 PM
Just out in @bmj.com, our "Uncertainties in Practice" article on #LATP vs #TRUS
We highlight evidence so far, discordance between recommendations (@UroWeb.bsky.social vs @NIHR.bsky.social vs #AUA) & need for nuance (!)
Not long now until #TranslateTrial...
bmj.com/content/387/bm…👈
We highlight evidence so far, discordance between recommendations (@UroWeb.bsky.social vs @NIHR.bsky.social vs #AUA) & need for nuance (!)
Not long now until #TranslateTrial...
bmj.com/content/387/bm…👈
LATP hits harder: +5.7% GG≥2 vs TRUS (p=0.031)! Fewer infections, slightly more pain & embarrassment. No abx needed. Costlier, slower—but sharper. #TRANSLATEtrial #ProstateCancer #LATP #TRUS #EAU25 #LancetOncology @axelmerseburger.bsky.social
March 24, 2025 at 11:36 AM
LATP hits harder: +5.7% GG≥2 vs TRUS (p=0.031)! Fewer infections, slightly more pain & embarrassment. No abx needed. Costlier, slower—but sharper. #TRANSLATEtrial #ProstateCancer #LATP #TRUS #EAU25 #LancetOncology @axelmerseburger.bsky.social